Efficacy of a once-monthly pill containing ibandronate and cholecalciferol on the levels of 25-hydroxyvitamin D and bone markers in postmenopausal women with osteoporosisopen access
- Authors
- Cho I.-J.; Chung H.-Y.; Kim S.-W.; Lee J.-W.; Lee T.-W.; Kim H.-S.; Kim S.-G.; Choi H.S.; Choi S.-H.; Shin C.S.; Oh K.-W.; Min Y.-K.; Koh J.-M.; Rhee Y.; Byun D.-W.; Chung Y.-S.; Park J.H.; Chung D.J.; Shong M.; Hong E.-G.; Lee C.B.; Baek K.H.; Kang M.-I.
- Issue Date
- 2015
- Publisher
- Korean Endocrine Society
- Keywords
- 25-hydroxyvitamin D; Bone markers; Cholecalciferol; Ibandronate
- Citation
- Endocrinology and Metabolism, v.30, no.3, pp 272 - 279
- Pages
- 8
- Indexed
- SCOPUS
KCI
- Journal Title
- Endocrinology and Metabolism
- Volume
- 30
- Number
- 3
- Start Page
- 272
- End Page
- 279
- URI
- https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/30153
- DOI
- 10.3803/EnM.2015.30.3.272
- ISSN
- 2093-596X
2093-5978
- Abstract
- Background: The present study evaluated the efficacy of a combination of ibandronate and cholecalciferol on the restoration of the levels of 25-hydroxyvitamin D (25[OH]D) and various bone markers in postmenopausal women with osteoporosis. Methods: This was a randomized, double-blind, active-controlled, prospective 16-week clinical trial conducted in 20 different hospitals. A total of 201 postmenopausal women with osteoporosis were assigned randomly to one of two groups: The IBN group, which received a once-monthly pill containing 150 mg ibandronate (n=99), or the IBN+ group, which received a once-monthly pill containing 150 mg ibandronate and 24,000 IU cholecalciferol (n=102). Serum levels of 25(OH)D, parathyroid hormone (PTH), and various bone markers were assessed at baseline and at the end of a 16-week treatment period.Results: After 16 weeks of treatment, the mean serum levels of 25(OH)D significantly increased from 21.0 to 25.3 ng/mL in the IBN+ group but significantly decreased from 20.6 to 17.4 ng/mL in the IBN group. Additionally, both groups exhibited significant increases in mean serum levels of PTH but significant decreases in serum levels of bone-specific alkaline phosphatase and C-telopeptide of type 1 collagen (CTX) at 16 weeks; no significant differences were observed between the groups. However, in subjects with a vitamin D deficiency, IBN+ treatment resulted in a significant decrease in serum CTX levels compared with IBN treatment. Conclusion: The present findings demonstrate that a once-monthly pill containing ibandronate and cholecalciferol may be useful for the amelioration of vitamin D deficiency in patients with postmenopausal osteoporosis. Moreover, this treatment combination effectively decreased serum levels of resorption markers, especially in subjects with a vitamin D deficiency, over the 16-week treatment period. © 2015 Korean Endocrine Society.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 2. Clinical Science > Department of Endocrinology and Metabolism > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.